{
    "clinical_study": {
        "@rank": "61923", 
        "acronym": "Sirolimus", 
        "arm_group": {
            "arm_group_label": "Sirolimus", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Liver transplant patients treated with tacrolimus, who are clinically stable for at least 3\n      months, who are on antihypertensive drug treatment, and/or have renal dysfunction due to\n      tacrolimus use, will be eligible for conversion to sirolimus and withdrawl of Tacrolimus.\n      The study will include 60 subjects, both male and female, age 5-30. This study will evaluate\n      allograft function by serial clinical lab testing, the pharmacokinetics of sirolimus and\n      tacrolimus, the glomerular filtration rate (GFR) as measured clearance of iothalamate, and\n      the potential side effect of sirolimus, such as marrow suppression and hyperlipidemia. Two\n      pharmacokinetic evlauations are planned: once around the third post-transplant month and\n      another one at about 12 months. Expected outcomes are, a better understanding of sirolimus\n      pharmacokinetic parameters over time in pediatric/adult liver recipients and early efficacy\n      and safety data of the sirolimus as a non-nephrotoxic alternative to tacrolimus."
        }, 
        "brief_title": "Pharmacokinectics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity", 
        "completion_date": {
            "#text": "January 2010", 
            "@type": "Actual"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "The study plans to collect Pharmacokinetic data for Tacrolimus and Sirolimus alone and in\n      combination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recipients of primary liver (cadaver/liver, whole/segmental) transplants 5-    30\n             years old.\n\n          -  Rejection-free post-transplant course for at least 3 months\n\n          -  Renal dysfunction (15% decrease in age-adjusted calculated creatinine clearance)\n\n          -  Hypertension requiring anti-hypertensive mediations.\n\n          -  Informed consent.\n\n          -  Weight \u226515 kg.\n\n        Exclusion Criteria:\n\n          -  Rejection or infections within 3 months of enrollment.\n\n          -  Intent to continue TAC\n\n          -  Active participation in ongoing studies of immunosuppressive agents.\n\n          -  Lack of informed consent.\n\n          -  Pregnant or breast feeding\n\n          -  HIV positive"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "3", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 29, 2010", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709136", 
            "org_study_id": "07100379"
        }, 
        "intervention": {
            "arm_group_label": "Sirolimus", 
            "description": "Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the PCTRC , and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.", 
            "intervention_name": "Sirolimus", 
            "intervention_type": "Drug", 
            "other_name": [
                "Sirolimus (Rapamycin)", 
                "Tacrolimus (FK506)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 16, 2012", 
        "number_of_arms": "1", 
        "official_title": "Pharmacokinectics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Early Nephrotoxicity and/or Hypertension Due to Tacrolimus", 
        "overall_official": {
            "affiliation": "UPitt", 
            "last_name": "Rakesh Sindhi", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Acute rejection - incidence and severity-", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Acute rejection - incidence and severity-", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Acute rejection - incidence and severity-", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Incidence of infection-", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Incidence of infection-", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Incidence of infection-", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Leukopenia", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Leukopenia", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Leukopenia", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "thrombocytopenia", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "thrombocytopenia", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "thrombocytopenia", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Hyperlipidemia", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Hyperlipidemia", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Hyperlipidemia", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "diabetes mellitus", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "diabetes mellitus", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "diabetes mellitus", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Malignancy", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Malignancy", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Malignancy", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Adverse events requiring discontinuation of any immunosuppressive agent", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Adverse events requiring discontinuation of any immunosuppressive agent", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Adverse events requiring discontinuation of any immunosuppressive agent", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709136"
        }, 
        "responsible_party": {
            "name_title": "Rakesh Sindhi, MD, FACS", 
            "organization": "Children's Hospital of Pittsburgh of UPMC"
        }, 
        "secondary_outcome": [
            {
                "measure": "Discontinuation/decrease in antihypertensive medications-", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Discontinuation/decrease in antihypertensive medications-", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Discontinuation/decrease in antihypertensive medications-", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Hypertension requiring treatment", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Hypertension requiring treatment", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Hypertension requiring treatment", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Resolution of renal dysfunction", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Resolution of renal dysfunction", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Resolution of renal dysfunction", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "PK parameters for tacrolimus and sirolimus", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "PK parameters for tacrolimus and sirolimus", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "PK parameters for tacrolimus and sirolimus", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "University of Pittsburgh", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pittsburgh", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2005", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2011", 
        "why_stopped": "Sirolimus usage discontinued since black box warning"
    }
}